Enalapril(Eletriptan, Amprace, Vaseretic) is an inhibitor of angiotensin-converting enzyme (ACE), primarily used to treat hypertension, heart failure, and asymptomatic left ventricular dysfunction. It also attenuates frailty in aging mice.

Enalapril(Eletriptan, Amprace, Vaseretic) is an inhibitor of angiotensin-converting enzyme (ACE), primarily used to treat hypertension, heart failure, and asymptomatic left ventricular dysfunction. It also attenuates frailty in aging mice.

Escitalopram ((S)-Citalopram), (S)-+ Citalopram)) is a selective serotonin reuptake inhibitor (SSRI) with a Ki value of 0.89 nM. Escitalopram has approximately 30-fold higher binding affinity than its R(-)-enantiomer and exhibits selectivity over both norepinephrine transporter (NET) and dopamine transporter (DAT).

Escitalopram ((S)-Citalopram), (S)-+ Citalopram)) is a selective serotonin reuptake inhibitor (SSRI) with a Ki value of 0.89 nM. Escitalopram has approximately 30-fold higher binding affinity than its R(-)-enantiomer and exhibits selectivity over both norepinephrine transporter (NET) and dopamine transporter (DAT).

Escitalopram ((S)-Citalopram), (S)-+ Citalopram)) is a selective serotonin reuptake inhibitor (SSRI) with a Ki value of 0.89 nM. Escitalopram has approximately 30-fold higher binding affinity than its R(-)-enantiomer and exhibits selectivity over both norepinephrine transporter (NET) and dopamine transporter (DAT).

Estramustine(NSC-89201, LEO275) is used to treat hormone-resistant prostate cancer and stabilize microtubule dynamics. It acts as an anti-mitotic and anti-microtubule agent and disrupts microtubule disassembly. It inhibits the binding of MAPs 1 and 2 to taxol-stabilized microtubules, hinders microtubule assembly, and promotes the disassembly of MAP-2-associated microtubules.

Escitalopram ((S)-Citalopram), (S)-+ Citalopram)) is a selective serotonin reuptake inhibitor (SSRI) with a Ki value of 0.89 nM. Escitalopram has approximately 30-fold higher binding affinity than its R(-)-enantiomer and exhibits selectivity over both norepinephrine transporter (NET) and dopamine transporter (DAT).

Estramustine(NSC-89201, LEO275) is used to treat hormone-resistant prostate cancer and stabilize microtubule dynamics. It acts as an anti-mitotic and anti-microtubule agent and disrupts microtubule disassembly. It inhibits the binding of MAPs 1 and 2 to taxol-stabilized microtubules, hinders microtubule assembly, and promotes the disassembly of MAP-2-associated microtubules.

Estramustine(NSC-89201, LEO275) is used to treat hormone-resistant prostate cancer and stabilize microtubule dynamics. It acts as an anti-mitotic and anti-microtubule agent and disrupts microtubule disassembly. It inhibits the binding of MAPs 1 and 2 to taxol-stabilized microtubules, hinders microtubule assembly, and promotes the disassembly of MAP-2-associated microtubules.

Estramustine(NSC-89201, LEO275) is used to treat hormone-resistant prostate cancer and stabilize microtubule dynamics. It acts as an anti-mitotic and anti-microtubule agent and disrupts microtubule disassembly. It inhibits the binding of MAPs 1 and 2 to taxol-stabilized microtubules, hinders microtubule assembly, and promotes the disassembly of MAP-2-associated microtubules.